- Stocks
- Pharma & Healthcare
- Granules India
Granules India share price
NSE: GRANULESPharma & HealthcareDrug Manufacturers - Specialty & Generic
Granules India at a glance
Granules India (NSE: GRANULES) closed at ₹802.85 on 19 Oct 2026, down 2.45% on the day. With a market capitalisation of ₹19,894 Cr, it ranks 361st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 32.8× trailing earnings, against a return on equity of 11.7% in FY26. Over the past year the share price has risen 41.1%. Its 52-week range is ₹529.85 (25 Nov 2025) to ₹923.65 (15 Sep 2026); the last close is 13.1% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹11 Cr (+49.3% year on year) and net profit −₹1 Cr (−267.9%), on a consolidated basis. Promoters held 38.02% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹19,894 CrRank 361 on NSE
- P/E (trailing)
- 32.8×
- Price to book
- 3.03×FY26
- EPS (TTM)
- ₹0.99to Q4 FY26
- ROE
- 11.7%FY26
- ROCE
- 16.2%FY26
- Debt to equity
- 0.26FY26
- Net profit margin
- 11.1%FY26
- Book value / share
- ₹205.21FY26
- 52-week high
- ₹923.6515 Sep 2026
- 52-week low
- ₹529.8525 Nov 2025
- 1-year return
- +41.1%
- RSI (14-day)
- 41.5
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −2.45% | +0.5% | −8.0% | −8.6% | +41.1% |
Granules India quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹10 Cr | ₹9 Cr | ₹10 Cr | ₹8 Cr | ₹14 Cr | ₹15 Cr | ₹16 Cr | ₹11 Cr |
| Revenue YoY | — | — | — | — | +38.6% | +71.5% | +64.0% | +49.3% |
| Net profit | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | −₹1 Cr |
| Net profit YoY | — | — | — | — | +20.6% | +880.0% | +316.7% | −267.9% |
| Net margin | 3.5% | 1.2% | 3.0% | 10.2% | 3.0% | 6.7% | 7.7% | −11.5% |
| EPS | ₹0.20 | ₹0.07 | ₹0.20 | ₹0.52 | ₹0.22 | ₹0.52 | ₹1.09 | −₹0.84 |
Granules India financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹3,238 Cr | ₹3,765 Cr | ₹4,512 Cr | ₹4,506 Cr | ₹4,482 Cr | ₹5,366 Cr |
| Operating profit | ₹704 Cr | ₹558 Cr | ₹687 Cr | ₹547 Cr | ₹629 Cr | ₹795 Cr |
| Net profit | ₹549 Cr | ₹413 Cr | ₹517 Cr | ₹405 Cr | ₹502 Cr | ₹595 Cr |
| EPS (₹) | ₹22.00 | ₹17.00 | ₹21.00 | ₹17.00 | ₹21.00 | ₹24.00 |
| Cash from operations | ₹432 Cr | ₹332 Cr | ₹739 Cr | ₹439 Cr | ₹867 Cr | ₹793 Cr |
| Total debt | ₹334 Cr | ₹234 Cr | ₹149 Cr | ₹69 Cr | ₹312 Cr | ₹297 Cr |
| Shareholders' equity | ₹2,173 Cr | ₹2,587 Cr | ₹2,835 Cr | ₹3,226 Cr | ₹3,716 Cr | ₹5,085 Cr |
Granules India shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 23 Feb 2026 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 38.82% | 38.82% | 38.82% | 38.02% | 38.02% | 38.02% |
| Foreign institutions | 13.24% | 14.09% | 13.55% | 13.79% | 15.31% | 17.50% |
| Domestic institutions | 23.53% | 17.92% | 17.48% | 18.51% | 17.01% | 16.11% |
| Non-institutions | 24.41% | 29.17% | 30.15% | 29.69% | 29.66% | 28.38% |
Granules India vs peers
The listed Pharma & Healthcare companies nearest to Granules India by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| PGHHProcter Gamble | ₹7,110.00 | −0.84% | −50.1% | ₹23,080 Cr | 26.9 | 62.3% |
| PIRPHYTOPiramal Phytoca | — | — | — | ₹21,083 Cr | — | — |
| SAGILITYSAGILITY | ₹43.95 | −3.09% | −5.2% | ₹20,574 Cr | 22.2 | 9.6% |
| IGLIndraprastha | ₹142.29 | −0.51% | −34.1% | ₹19,921 Cr | 12.9 | 27.0% |
| GRANULESGranules India | ₹802.85 | −2.45% | +41.1% | ₹19,894 Cr | 32.8 | 11.7% |
| COHANCECohance Lifesciences | ₹456.50 | −1.76% | −49.6% | ₹17,464 Cr | 97.8 | 15.8% |
| PFIZERPfizer | ₹3,805.50 | −0.12% | −28.4% | ₹17,409 Cr | 24.1 | 17.2% |
Ask anything about Granules India
Pivot answers on the live chart with evidence you can check, and tests strategies against GRANULES's own history. Try: “Why has GRANULES moved over the last three months?” · “Backtest a 50-day moving-average crossover on GRANULES over five years” · “Compare GRANULES with PGHH on margins and valuation”
Frequently asked questions about Granules India
What is the share price of Granules India today?
Granules India (NSE: GRANULES) last closed at ₹802.85 on 19 Oct 2026. Its 52-week high is ₹923.65 and its 52-week low is ₹529.85.
What is the market cap of Granules India?
Granules India's market capitalisation is ₹19,894 Cr (₹19,894 Cr) at the 19 Oct 2026 close, ranking 361st among the NSE companies Pivot tracks.
What is the P/E ratio of Granules India?
Granules India trades at a trailing P/E of 32.8. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 24.1.
What is the ROE and ROCE of Granules India?
Return on equity was 11.7% in FY26 and return on capital employed was 16.2% in FY26 (consolidated figures).
Is Granules India a debt-free company?
No. Granules India's debt-to-equity ratio was 0.26 in FY26, with total debt of ₹297 Cr.
What were Granules India's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Granules India reported revenue of ₹11 Cr, +49.3% year on year, and net profit of −₹1 Cr, −267.9% year on year.
How has Granules India stock performed over the last year?
Granules India's share price has risen 41.1% over the past year, −8.6% over three months and −8.0% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Granules India?
As of 30 Jun 2026: promoters 38.02%, foreign institutions 17.50%, domestic institutions 16.11%, non-institutions 28.38%.
Who are Granules India's competitors?
The listed Pharma & Healthcare companies closest to Granules India by market cap are Procter Gamble, Piramal Phytoca, SAGILITY, Indraprastha, Cohance Lifesciences and Pfizer.
Is Granules India a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Granules India's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GRANULES against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with G · all NSE stocks · this page as text